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SUMMARY 1 
Influenza virus is a major human pathogen that causes annual epidemics and 2 
occasional pandemics. Moreover, the virus causes outbreaks in poultry and other 3 
animals, such as pigs, requiring costly and laborious countermeasures. Therefore, 4 
influenza virus has a substantial impact on health and the global economy. Here, we 5 
review entry of this important pathogen into target cells, an essential process by 6 
which viral genomes are delivered from extracellular virions to sites of 7 
transcription/replication in the cell nucleus. We summarize current knowledge on the 8 
interaction of influenza viruses with their receptor, sialic acid, and highlight the 9 
ongoing search for additional receptors. We describe receptor-mediated endocytosis 10 
and the recently discovered macropinocytosis as alternative virus uptake pathways, 11 
and illustrate the subsequent endosomal trafficking of the virus with advanced live 12 
microscopy techniques. Release of virus from the endosome and import of the viral 13 
ribonucleoproteins into the host cell nucleus are also outlined. Although a focus has 14 
been on viral protein function during entry, recent studies have revealed exciting 15 
information on cellular factors required for influenza virus entry. We highlight these, 16 
and discuss both established entry inhibitors targeting viral and host factors, as well 17 
as the latest prospects for designing novel ‘anti-entry’ compounds. New entry 18 
inhibitors are of particular importance for current efforts to develop the next 19 
generation of anti-influenza drugs – entry is the first essential step of virus replication 20 
and is an ideal target to block infection efficiently.  21 
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INTRODUCTION 22 
Influenza A virus (IAV), the causative agent of influenza, is a large burden to the 23 
economy and public health world-wide.  With waterfowl as the primary reservoir the 24 
virus is able to infect a wide variety of birds and mammals, including humans. Due to 25 
this trait, zoonotic spillovers occur occasionally and can lead to pandemics with 26 
severe consequences for the human population.  The swine origin H1N1 virus from 27 
the 2009 pandemic and the H5N1 and H7N9 avian influenza viruses are recent 28 
examples of animal viruses that acquired the potential to infect and cause disease in 29 
humans. A detailed understanding of the viral lifecycle is required to assess or 30 
predict the impact of circulating as well as newly emerging viruses but also to 31 
develop anti-influenza drugs. The entry process of the virus represents a favorable 32 
target for drug development since inhibition of this first step of virus infection should 33 
result in an efficient block of virus propagation. One possibility is to target viral 34 
proteins essential for entry, e.g. the receptor-binding protein hemagglutinin (HA). An 35 
alternative approach is to target cellular proteins required for entry. While in the latter 36 
case toxicity could represent an obstacle this strategy would offer the advantage that 37 
resistance is less likely to occur. In addition, many viruses use similar entry routes 38 
and so it is conceivable that broad-spectrum antivirals could be developed. 39 
IAV belongs to the family Orthomyxoviridae and possesses a segmented, negative-40 
sense RNA genome. Unlike most RNA viruses, IAV replicates in the nucleus. 41 
Therefore, the virus has to overcome several barriers on its way to the site of 42 
replication and, simultaneously, avoid being recognized by the innate immune 43 
system. IAV entry is a dynamic process which requires the completion of six 44 
individual steps: Attachment to target cells (I), internalization into cellular 45 
compartments (II), endosomal trafficking to the perinuclear region (III), fusion of viral 46 
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and endosomal membranes (IV), uncoating (V), and import of the viral genome into 47 
the nucleus (VI) (fig. 1).  Here, we summarize how the virus manages to successfully 48 
enter target cells and to transport its genetic material to the nucleus. Furthermore, we 49 
discuss which host factors are required by the virus to complete these processes and 50 
which inhibitors are available to block individual steps of the IAV entry pathway.   51 
 52 
INFLUENZA A VIRUS ATTACHMENT TO HOST CELLS 53 
Sialic acid is the receptor for influenza A virus 54 
The initial step of the viral entry process is the attachment of IAV to the host cell. The 55 
primary receptor for IAV is N-acetylneuraminic acid (also called sialic acid) and this 56 
receptor is recognized and bound by the viral membrane protein, HA (Palese and 57 
Shaw 2007). Sialic acid is the distal residue in oligosaccharide chains of N- and O-58 
linked glycoproteins and –lipids. Often, sialic acid is attached to the underlying 59 
galactose by α-2,3 or α-2,6 linkages. This linkage and the resulting structural 60 
consequences influence how well IAV can bind to its receptor.  61 
HA is a multifunctional IAV protein mediating virus attachment and fusion. There are 62 
18 different HA subtypes known of which 16 circulate in waterfowl and two subtypes 63 
(H17, H18) have been isolated from bats (Tong et al. 2012; Tong et al. 2013). Of 64 
note H17 and H18 do not bind to sialic acid; the receptor for these viruses is not yet 65 
known (Sun et al. 2013; Tong et al. 2013; Zhu et al. 2013b). HA is expressed as a 66 
trimer on the virion surface. The stalk region of HA containing the fusion peptide 67 
connects the HA to the virion envelope by a short hydrophobic sequence (Skehel and 68 
Wiley 2000). This region is heavily glycosylated on conserved epitopes, which 69 
appear to be required for stability and structure of the molecule (Roberts et al. 1993). 70 
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The globular head is also glycosylated but the glycosylation pattern and -type can be 71 
highly variable in different HA subtypes.  The receptor binding pocket (RBP) is 72 
located on the distal end of the HA trimer at the globular head (fig. 2a) and is highly 73 
conserved among different HA subtypes. Mutations in residues of the RBP and those 74 
in close proximity can drastically alter the receptor specificity of HA (Connor et al. 75 
1994; Liu et al. 2009; Xu et al. 2010). Sialic acid has been shown to occupy the 76 
whole RBP and to be the major point of contact between the virus and the cell  (Weis 77 
et al. 1988). The interaction between sialic acid and HA is believed to be of low 78 
affinity. To increase the overall strength of the interaction multiple HA molecules are 79 
used to bind to several glycoproteins resulting in high avidity-binding to the cell 80 
surface  (Sauter et al. 1989).  81 
The structure and conformation of HA determines receptor specificity of IAV. It is well 82 
established that avian strains prefer sialic acid receptors with a α-2,3 linkage, while 83 
human IAV strains generally possess a high receptor specificity for α-2,6 linked sialic 84 
acid (Weis et al. 1988; Gamblin et al. 2004; Stevens et al. 2006b). In addition, studies 85 
using glycan arrays have shown that modifications on the underlying sugar chains 86 
are also recognized by HA and influence the binding of HA to sialic acid (Stevens et 87 
al. 2006a). More recent data suggest that the linkage of sialic acid is not the only 88 
determinant of receptor binding specificity but that the topological structure of sialic 89 
acid contributes to specificity and affinity of HA binding to sialic acid. It was shown 90 
that human IAV strains preferentially bind to long, umbrella-shaped sialic acid 91 
molecules with α-2,6 linkage, while avian strains generally bind to short sialic acid 92 
molecules that adopt a cone-like structure (Chandrasekaran et al. 2008). There are 93 
also reports that alternative glycosylations can be recognized by certain IAV strains, 94 
e.g. it was shown that N-glycolylneuraminic acid linked to galactose by α-2,3 linkage 95 
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can serve as receptor for IAV in the duck intestine (Ito et al. 2000).Recent structural 96 
studies on receptor binding of H5 and H7 viruses further developed our 97 
understanding of differential receptor specificity: For an H5N1 virus that had been 98 
selected to transmit in the ferret model it was shown that binding of α-2,6 sialic acid 99 
occurred in a similar orientation as in pandemic human viruses (Xiong et al. 2013a). 100 
In contrast, the orientation of sialic acid was different when the avian H5 was 101 
analyzed in combination with α-2,6 sialic acid. HA from an H7N9 virus that has 102 
recently emerged in China was able to bind α-2,6 sialic acid efficiently but in a 103 
different orientation compared to human pandemic viruses (Steinhauer 2013; Xiong 104 
et al. 2013b). Moreover, these recent studies also suggest that not only efficient 105 
binding to α-2,6 sialic acid might be required for human receptor specificity but also a 106 
reduction in binding efficiency to α-2,3 sialic acid. For the impact of receptor 107 
specificity on tropism, host range and pathogenicity of IAV we refer to (Matrosovich 108 
et al. 2009; Imai and Kawaoka 2012; Wilks et al. 2012). 109 
Often, virus entry is a multi-step process in which abundant, low affinity receptors are 110 
utilized for initial contact of viral particles with the cell. Subsequently, binding of high 111 
affinity receptors results in complete attachment and may trigger uptake of a particle. 112 
While it is generally accepted that sialic acid is the main receptor for IAV, there is still 113 
debate whether IAV requires additional host factors for successful attachment and 114 
entry into target cells. It has been observed that IAV binding to sialylated receptors 115 
does not always result in internalization of the virus into the host cell (Carroll and 116 
Paulson 1985). Furthermore, some desialylated cells retain the ability to bind IAV 117 
(Stray et al. 2000; Thompson et al. 2006) indicating that sialic acid might not be the 118 
sole receptor required for IAV attachment. Annexin V and 6-sulfo sialyl Lewis X 119 
receptors have been proposed as potential additional receptors for IAV attachment 120 
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(table 1) (Huang et al. 1996; Gambaryan et al. 2008).  Furthermore, IAV was able to 121 
attach to but not infect cells with a defect in complex N-glycosylation, suggesting the 122 
requirement of an additional factor other than sialic acid for efficient virus infection 123 
(Chu and Whittaker 2004). These results were later refined as it was found that 124 
proteins containing N-linked glycans are of importance for virus entry via 125 
macropinocytosis while clathrin-mediated endocytosis (both discussed later) was not 126 
affected by the absence of N-linked glycosylation and that entry of IAV was 127 
completely dependent on the presence of sialic acid (de Vries et al. 2012). For 128 
dendritic cells and macrophages, there are studies indicating that C-type lectin 129 
receptors such as macrophage mannose receptor (MMR), macrophage galactose-130 
type lectin (MGL) and Dendritic Cell-Specific Intercellular adhesion molecule-3-131 
Grabbing Non-integrin (DC SIGN) may also act as receptors for IAV entry (Reading 132 
et al. 2000; Wang et al. 2008; Upham et al. 2010; Londrigan et al. 2011). However, it 133 
remains to be determined whether these receptors alone are sufficient or whether 134 
additional co-receptors are required for viral uptake.  135 
Inhibitors of virus attachment 136 
Inhibition of virus attachment might be an attractive strategy for inhibiting IAV 137 
infection at the earliest step. Several approaches to block the interaction between HA 138 
and sialic acid have been proposed (table 2). Inhibitors can work by either binding to 139 
the HA globular head to prevent interactions with the receptor or they can act on the 140 
receptor sialic acid. Monoclonal antibodies (mAbs) that bind HA are the most 141 
prominent example of inhibitors acting on the virus. Numerous mAbs have been 142 
generated and found to inhibit virus replication in cell culture and animal models 143 
(reviewed in (Martinez et al. 2009)). Importantly, most mAbs which target the globular 144 
head of HA bind and neutralize only the HA they were generated against and a few 145 
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closely related HAs. However, in recent years broadly neutralizing mAbs that bind 146 
conserved epitopes in HA have been developed and these antibodies show promise 147 
as inhibitors of many different influenza virus strains (Corti and Lanzavecchia 2013). 148 
Two types of antibodies can be distinguished: Antibodies binding conserved epitopes 149 
in the globular head (Yoshida et al. 2009; Whittle et al. 2011; Ekiert et al. 2012) and 150 
antibodies recognizing conserved sites in the stem of HA (reviewed in (Ekiert and 151 
Wilson 2012)). The latter type of antibodies do not inhibit attachment but block fusion 152 
and are therefore discussed in the section on viral fusion. Antibodies that recognize 153 
conserved epitopes in the globular head can block attachment of different influenza 154 
virus subtypes and hold promise for the development of antiviral drugs.  155 
Besides the mAbs soluble sialic acid analogues that block the RBP of HA have been 156 
suggested as potent inhibitors of IAV infection. Both, soluble α-2,3 and α-2,6 linked 157 
sialic acid, can be found in mucus as well as in exosomes released from airway 158 
epithelial cells (Baum and Paulson 1990; Kesimer et al. 2009; Roberts et al. 2011). 159 
Recent studies propose several synthetic receptor mimics that bind to the RBP for 160 
use as antiviral compounds (Kimura et al. 2000; Terabayashi et al. 2006; Nicol et al. 161 
2012).  It was also shown that sialic acid peptide mimics that bind the RBP of HA can 162 
block infection with seasonal H1N1 and H3N2 viruses (Matsubara et al. 2010).  163 
Moreover, potent antiviral effects of liposomes loaded with such sialic acid analogues 164 
were observed (Hendricks et al. 2013). In addition, the development of receptor-165 
binding compounds that decrease the amount of available binding partners for HA, 166 
has also been followed (Matsubara et al. 2009). An interesting strategy to inhibit virus 167 
attachment is the use of sialidases, which remove sialic acid from epithelial cell 168 
surfaces.  DAS181 is a compound consisting of a bacterial sialidase derived from 169 
Actinomyces viscosus linked to amphiregulin that is currently in phase II clinical trials. 170 
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The conjugation of the sialidase to amphiregulin containing an epidermal-growth-171 
factor-like domain is required for the effective targeting of epithelial cells. DAS181 172 
possesses antiviral activity against a broad variety of influenza A and B viruses in cell 173 
culture (Nicholls et al. 2013).  174 
 175 
ENTRY ROUTES USED FOR INFLUENZA A VIRUS INTERNALIZATION 176 
Internalization of IAV 177 
Upon attachment to the host cell IAV is taken up into the cell. Imaging studies 178 
revealed early that the virus enters the cell by receptor-mediated endocytosis 179 
(Patterson et al. 1979; Matlin et al. 1981; Yoshimura et al. 1982). It was shown that 180 
cold-bound virus was –upon raising the temperature to 37°C- not fusing at the 181 
plasma membrane. Virus uptake occurred within minutes after the temperature raise 182 
as the half life time of attached viral particles to become resistant to treatment with 183 
sialidases was between 10-15 minutes (Matlin et al. 1981). IAV was internalized into 184 
mainly clathrin-coated but also into uncoated vesicles. This already suggested that 185 
IAV is able to utilize multiple endocytosis routes, not only clathrin-mediated 186 
endocytosis. Later, it was demonstrated that the virus can still infect cells defective in 187 
clathrin- and caveolin-dependent pathways (Sieczkarski and Whittaker 2002).  In line 188 
with these data, imaging studies with single viral particles showed that IAV can utilize 189 
clathrin- and non-clathrin entry routes in parallel (Rust et al. 2004). Recent studies 190 
identified macropinocytosis as alternative pathway exploited by IAV (de Vries et al. 191 
2011). Macropinocytosis refers to the uptake of large-sized cargo through the actin-192 
dependent formation of large endocytic vesicles called macropinosomes. IAV enters 193 
the cell by clathrin-mediated endocytosis in the absence of serum and this pathway 194 
can be efficiently blocked using the dynamin inhibitor dynasore. However, if serum is 195 
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present during infection, IAV is taken up into cells by dynamin-dependent and –196 
independent entry routes. A complete block of internalization was only achieved 197 
when cells were treated with dynasore in combination with EIPA (de Vries et al. 198 
2011). EIPA is an inhibitor of Na+/H+ exchangers, which was shown to block 199 
macropinocytosis by preventing elevation of the cytosolic pH which in turn affects 200 
activation of GTPases required for actin remodeling (Koivusalo et al. 2010). Further 201 
studies showed that the choice of entry route is likely to be cell type dependent (De 202 
Conto et al. 2011) and that filamentous IAV preferentially uses macropinocytosis for 203 
internalization (Rossman et al. 2012). The latter can explain earlier observations on 204 
the entry process of filamentous IAV: It had been demonstrated that acidification of 205 
endosomes was required but dynamin seemed to be dispensable (Sieczkarski and 206 
Whittaker 2005). 207 
To date it is not clear whether binding of HA to sialylated glycans is sufficient to 208 
initiate internalization of viral particles. Several studies indicate that additional 209 
receptors may be required to orchestrate virus uptake (table 1).  It was demonstrated 210 
that the formation of clathrin-coated pits occurs at faster pace at virus-attached spots 211 
than in other areas at the cell surface (Rust et al. 2004). These data indicate that IAV 212 
specifically triggers its uptake via clathrin-mediated endocytosis and is therefore 213 
likely to interact with additional cell surface receptors to activate downstream 214 
signaling processes required for internalization.  The adaptor protein Epsin-1 215 
localizes to attachment sites of IAV and this coincides with the formation of clathrin-216 
coated pits at that site. In addition, knockdown of Epsin-1 inhibited clathrin-mediated 217 
endocytosis of IAV but not of other ligands such as transferrin (Chen and Zhuang 218 
2008). Therefore, Epsin-1 is an adaptor recruited specifically for clathrin-mediated 219 
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IAV entry indicating that IAV triggers certain pathways that differ from classical 220 
clathrin-mediated endocytosis events.  221 
There is growing evidence that receptor tyrosine kinases (RTKs) may play an 222 
important role in the uptake of IAV particles. It could be shown that IAV attachment 223 
activates EGFR and that activated EGFR promotes virus uptake into target cells. 224 
Similar results were obtained for the c-Met kinase so the authors speculate that IAV 225 
attachment to the cell surface results in lipid raft formation which serves as signaling 226 
platform to trigger RTK activation leading to virus internalization (Eierhoff et al. 2010). 227 
Recently, it has been demonstrated that activation of phosphoinositide-specific 228 
phospholipase γ1 (PLCγ1) - which acts downstream of EGFR - is required for entry 229 
of H1N1 viruses (Zhu et al. 2013a). Interestingly, in this study both, H1N1 and H3N2 230 
viruses were able to activate EGFR following attachment but only H1N1 viruses also 231 
activated PLCγ1. These results indicate that different IAV subtypes are capable of 232 
specifically activating distinct signaling pathways to facilitate entry. Supporting 233 
evidence for involvement of RTKs in IAV entry came from inhibitor studies showing 234 
that many RTK inhibitors decrease IAV internalization by macropinocytosis (de Vries 235 
et al. 2011). Indeed, N-linked glycans, present on membrane receptors, have shown 236 
to be important for IAV entry in the presence of serum (de Vries et al. 2012). 237 
Nevertheless, the authors clearly demonstrate that IAV entry was dependent on sialic 238 
acid under all experimental conditions. In summary there is evidence for activation of 239 
common RTK cascades involving PKC, MEK/ERK and PI3K/AKT by IAV infection, 240 
but it remains to be determined how these pathways contribute to virus entry into 241 
host cells.  242 
 243 
 244 
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Inhibitors of internalization 245 
Compounds that inhibit virus endocytosis would be of great clinical use as a large 246 
array of viruses enter cells by endocytosis. However, most inhibitors used in tissue 247 
culture experiments such as dynasore or EIPA are cytotoxic in higher concentrations 248 
and prolonged exposure and are therefore not suitable for clinical use. Also RTK 249 
inhibitors are problematic as most currently available compounds lack specificity and 250 
target a variety of RTK. An interesting compound is Lj001 which affects membrane 251 
fluidity and -curvature through (1)02-mediated lipid oxidation. Therefore, its antiviral 252 
activity is restricted to enveloped viruses (Wolf et al. 2010; Vigant et al. 2013).  253 
 254 
ENDOSOMAL TRAFFICKING OF INFLUENZA A VIRUS 255 
From early to late endosomes 256 
The endosomal system is well described as a cellular sorting system for incoming 257 
extracelluar material and intracellular vesicles (reviewed in (Mellman 1996)). 258 
Influenza viruses are taken up by endocytosis or macropinocytosis and exploit the 259 
transport system via distinct endosomal stages and concomitant changes in pH to 260 
release their viral RNPs into the cytoplasm. Upon internalization by either uptake 261 
pathway, receptor-mediated endocytosis or macropinocytosis, the virus first localizes 262 
to early endosomes and then reaches late endosomes. Endosomal trafficking is 263 
known to be a non-linear pathway with a multitude of different branches leading to 264 
degradation of extracellular compounds and membrane recycling (Steinman et al. 265 
1983). Here, we focus on how IAV exploits the endosomal pathway.  266 
Before influenza A virus reaches its fusion site it has to pass different stages of the 267 
endocytic machinery, which is assembled and constantly renewed around the 268 
internalized virus particles (Rust et al. 2004; Cocucci et al. 2012). A difficulty in 269 
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detecting these stages of viral trafficking is the short time span viruses remain in the 270 
endosomal compartment. Penetration of viral ribonucleoprotein complexes (vRNPs) 271 
into the cytoplasm can be detected already after several minutes following virus 272 
binding to the cell and vRNPs reach the nucleus within the first hour (Martin and 273 
Helenius 1991). For the aim of visualizing viruses along the endosomal trafficking 274 
pathway, synchronized infection was established as an important tool that allows 275 
monitoring early infection events (Matlin et al. 1981). It has been demonstrated that 276 
endosomal trafficking of the virus involves actin- and microtubule-dependent 277 
processes (Nielsen et al. 1999; Sun and Whittaker 2007; De Conto et al. 2012). 278 
Using single virus trajectories from imaging fluorescently-labelled virions, viral 279 
transport was dissected into three different stages (Lakadamyali et al. 2003): First, 280 
the virus is transported in the cell-periphery and this process was demonstrated to be 281 
actin-dependent. This is followed by the second stage which is marked by rapid 282 
dynein-directed movement. Finally, moving of virions along microtubules to the 283 
perinuclear region can be defined as stage three. This transport pattern correlates to 284 
a large extend with well-established endosomal routes: Early endosomes (EE) 285 
containing cargo are transported away from the cell surface via actin dependent 286 
transport. EEs are then transported via the motorproteins kinesin-1 and dynein along 287 
microtubules towards the nucleus. Simultaneously, EEs constantly exchange 288 
vesicles with the trans Golgi network thereby undergoing a maturation process 289 
(reviewed in (Huotari and Helenius 2011)). Rab5 and additional proteins such as 290 
EEA1 (early endosomal autoantigen 1) and PI(3)K (phosphatidyl-inositol-3-OH 291 
kinase), are major regulators of this maturation process and are used as marker 292 
proteins to stain EEs (fig. 3)  (Bucci et al. 1992; Mu et al. 1995; Simonsen et al. 1998; 293 
Christoforidis et al. 1999a; Christoforidis et al. 1999b; Fujioka et al. 2011). Late 294 
endosomes (LE) are formed from EEs during their microtubule-dependent transport 295 
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into the perinuclear region by acquiring intraluminal vesicles during vesicle exchange 296 
with lysosomes or other late endosomes (Luzio et al. 2007; Huotari and Helenius 297 
2011). LE contain integral membrane proteins such as LAMP1 (lysosomal membrane 298 
protein 1) and their pH drops down from 6.8-5.9 in EEs to 6.0-4.8 in LE (Maxfield and 299 
Yamashiro 1987). The progression from EE to LE is indicated by the so called “Rab 300 
Switch” from Rab5 for EE to Rab 7 for LE (Rink et al. 2005). Rab proteins are cellular 301 
GTPases that are recruited to vesicle membranes and play a key role in regulating 302 
endosomal trafficking. Different Rab proteins are required for different steps in 303 
vesicular transport, although some of them are following their endosomal 304 
compartments throughout maturation of endosomes (Zerial and McBride 2001).  305 
With respect to IAV infection, both Rab5 and Rab7 have been shown to be required 306 
(Sieczkarski and Whittaker 2003). Moreover, protein kinase C βII (PKCβII) has been 307 
linked to IAV trafficking in endosomes. Infection of cells pretreated with inhibitors 308 
against PKCβII leads to the accumulation of viral particles in LE, without fusion taking 309 
place (Sieczkarski et al. 2003). Other important players in LE trafficking are histone 310 
deacetylases. Depletion of histone deacetylase 8 (HDAC8) resulted in dysregulation 311 
of microtubule organization, centrosome function and maturation of LE to lysosomes 312 
and subsequently in a decrease in viral replication (Yamauchi et al. 2011). 313 
Furthermore, Cullin 3 which is a scaffolding protein for an E3 ubiquitin ligase complex 314 
was shown to be required for IAV entry at the level of LE (Huotari et al. 2012). 315 
Importantly, depletion of cullin 3 also inhibited trafficking of other cargos such as 316 
epidermal growth factor (EGF) indicating that this pathway is required for transport of 317 
a variety of cargos and is not solely used by IAV.  318 
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FUSION OF INFLUENZA A VIRUS  319 
Fusion between viral and endosomal membrane 320 
Preceeding the nuclear transport of IAV fusion of viral and endosomal membranes is 321 
required to release vRNPs into the cytoplasm. This process is driven by a low pH 322 
environment and the class I fusion protein of IAV, the HA. LE posses an acidic 323 
environment and thus facilitate the induction of influenza virus HA-dependent fusion 324 
at pH 5.0 (Maeda and Ohnishi 1980; Daniels et al. 1985; White and Wilson 1987). 325 
Interestingly, HAs of different subtypes display varying pH optima for fusion and HAs 326 
of human isolates require lower pHs than avian isolates of the same subtype 327 
(Galloway et al. 2013). During the acidification process of endosomes, proton pumps 328 
which deliver protons into the endosomal lumen and thereby ensure stepwise 329 
acidification, exhibit a crucial function (Galloway et al. 1983; Perez and Carrasco 330 
1994). These so called v-ATPases consist of two complexes, one membrane 331 
associated V0 complex and a soluble cytosolic V1 complex, which hydrolyzes ATP 332 
as the driving force of acidification (reviewed in (Forgac 2007)). Once IAV is in the 333 
acidic environment of LE, HA undergoes conformational changes which expose the 334 
fusion peptide and position it towards the endosomal membrane (fig. 2b) (Carr and 335 
Kim 1993; Bullough et al. 1994; Chen et al. 1999). It was shown that intermediate 336 
stages dependent on pH and membrane proximity exist (Korte et al. 1999; Leikina et 337 
al. 2002). Following the final conformational changes, the fusion peptide is inserted 338 
into the target membrane which brings the viral and endosomal membranes into 339 
close proximity (Tsurudome et al. 1992; Weber et al. 1994; Durrer et al. 1996). Of 340 
note, while the crystal structures of pre- and post-fusion HA have been solved the 341 
structures of the intermediate stages are not known so far and can only be modeled 342 
based on the pre- and post-fusion structures. For the fusion process it was shown 343 
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that several HA trimers promote membrane fusion by simultaneous conformational 344 
changes and release of folding energy (Markovic et al. 2001). To proceed with fusion 345 
between viral and endosomal membranes, HA trimers tilt at the fusion site and the 346 
outer leaflets of the membranes interact with each other in a hemifusion stage 347 
(Tatulian et al. 1995; Chernomordik et al. 1998). Finally, both membranes fuse and a 348 
so-called fusion pore is established (Spruce et al. 1989; Melikyan et al. 1993a; 349 
Melikyan et al. 1993b). Through this fusion pore vRNPs can be released into the 350 
cytoplasm.  351 
Limited information is available regarding cellular factors required for fusion of IAV. 352 
As discussed above, the vATPase complex is essential for acidification of the 353 
endosome, a prerequisite for fusion. Only very recently, the tetraspanin CD81 has 354 
been identified as another cellular player in the fusion process (He et al. 2013). 355 
Approximately 50% of internalized IAV localized to CD81- and Rab5-positive 356 
endosomes and fusion was observed to occur in these vesicles. In the absence of 357 
CD81 fusion was reduced by 50%. It is currently unknown how CD81 contributes to 358 
fusion but CD81 seems to mark a productive entry route for IAV.  359 
Inhibitors of fusion 360 
Inhibition of viral fusion can be achieved by inhibition of acidification in endosomes 361 
(table 2). One of the most potent inhibitors for this purpose is Bafilomycin A1 (BafA1). 362 
Bafilomycins belong to the family of macrolide antibiotics that were shown to inhibit 363 
vacuolar-type proton pumps involved in viral entry (Bowman et al. 1988; Ochiai et al. 364 
1995). Similar effects were shown for diphyllin and SaliPhe, other v-type ATPase 365 
inhibitors (Huss and Wieczorek 2009; Konig et al. 2010; Muller et al. 2011). Small 366 
molecules that bind to the stem region of HA and thereby hinder the conformational 367 
changes required for fusion represent another class of fusion inhibitors. The first 368 
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compound of this group to be discovered was TBHQ which has been crystallized in 369 
complex with HA (Bodian et al. 1993; Russell et al. 2008). Later on, several 370 
compounds that act in a similar way have been described: BMY-27709, CL-385319, 371 
RO5464466, stachyflin and 4c (Luo et al. 1997; Plotch et al. 1999; Yoshimoto et al. 372 
1999; Vanderlinden et al. 2010; Zhu et al. 2011). Unfortunately, resistance mutations 373 
in HA can develop rapidly within few passages of the virus and confer resistance to 374 
this type of compound. Arbidol has also been identified as an inhibitor of membrane 375 
fusion. Mutations rendering viruses resistant to arbidol have been mapped to HA and 376 
seem to impact acid stability of HA (Leneva et al. 2009). Of note, arbidol is approved 377 
as anti-influenza drug in Russia. Alternatively, the stem region of HA can be targeted 378 
by broadly neutralizing antibodies as mentioned above (Corti and Lanzavecchia 379 
2013). Such antibodies bind to a region of HA that is conserved even between 380 
different subtypes and this enables the antibodies’ potential to inhibit many different 381 
strains of IAV (Okuno et al. 1993; Throsby et al. 2008; Ekiert et al. 2009; Sui et al. 382 
2009; Corti et al. 2011). While they do not prevent binding to the host cell they 383 
interfere with the conformational changes required for fusion. These antibodies 384 
represent promising drug candidates but also could help to design a vaccine that 385 
provides protection against a broad range of IAV strains. 386 
 387 
UNCOATING 388 
Release of vRNPs into the cytoplasm 389 
Upon fusion of viral and endosomal membranes IAV uncoating is completed with the 390 
release of the viral RNPs into the cytosol. This process requires coordinated action of 391 
the viral proteins M2 and M1. In the intact virus particle M1 forms a structured layer 392 
underneath the viral membrane which can be visualized by electron microscopy 393 
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(Ruigrok et al. 2000; Calder et al. 2010; Fontana et al. 2012; Fontana and Steven 394 
2013). It is assumed that M1 plays a crucial role for the architecture of the virion by 395 
linking the viral membrane containing the glycoproteins with the RNPs in the virus 396 
core. While the expression of viral glycoproteins can result in production of virus-like 397 
particles even in the absence of M1 the matrix protein is required for production of 398 
infectious virions (virus assembly is reviewed in (Rossman and Lamb 2011)). This is 399 
supported by the observation that M1 determines the shape of the virion: Exchange 400 
of M1 is sufficient to change the morphology of virions from spherical to filamentous 401 
(Roberts et al. 1998; Bourmakina and Garcia-Sastre 2003; Elleman and Barclay 402 
2004). It is currently unclear how M1 interacts with the viral membrane and/or 403 
glycoproteins; specific binding domains have not yet been mapped (Zhang and Lamb 404 
1996; Schmitt and Lamb 2005). For the interaction of M1 with the vRNPs it could be 405 
demonstrated that the middle domain of M1 is responsible for binding to NP on the 406 
RNP (Noton et al. 2007).  407 
During the uncoating process the interaction of M1 with the viral membrane as well 408 
as the interaction of M1 with the vRNPs has to be released in order to allow complete 409 
uncoating and subsequent transport of the RNPs into the nucleus. This requires the 410 
activity of the viral protein M2. M2 was identified in 1981 as the second protein 411 
encoded by segment 7 of IAV (Lamb and Choppin 1981). It was found to form 412 
tetramers that are present in virions (Zebedee and Lamb 1988; Holsinger and Lamb 413 
1991; Sugrue and Hay 1991)  and it was described to possess ion channel activity 414 
selective for monovalent ions (Pinto et al. 1992; Chizhmakov et al. 1996). 415 
Interestingly, the ion channel activity of M2 is regulated by pH: With lower pH the ion 416 
channel activity increases and histidine 37 of M2 is crucial for this regulation (Pinto et 417 
al. 1992).  The transmembrane pore of the channel is lined by a series of amino 418 
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acids that all lie on the same side of an alpha-helix; four of these helices from the 419 
four monomers form the channel (Grambas et al. 1992; Pinto et al. 1992; Wang et al. 420 
1993; Stouffer et al. 2008). During the entry process of IAV the ion channel activity of 421 
M2 is required for uncoating: Upon acidification of the endosome M2 mediates proton 422 
influx from the endosome into the virion resulting in a decrease of the pH within the 423 
virus particle (Wharton et al. 1994). This M2-mediated change in pH is required for 424 
the detachment of M1 from the vRNPs resulting in the release of the vRNPs into the 425 
cytoplasm  (Zhirnov 1990). Furthermore, it was observed that M1 separates from the 426 
RNPs before they are imported into the nucleus (Bukrinskaya et al. 1982; Martin and 427 
Helenius 1991). Interestingly, this initial RNP nuclear import can be blocked by 428 
expression of M1 but brief low pH treatment can in turn relieve the block mediated by 429 
M1 (Bui et al. 1996). These observations have lead to the current model in which the 430 
pH drop in the virion within the endosome causes conformational changes in M1 and 431 
subsequently the interaction between the RNPs and M1 is weakened or lost. The 432 
changes in M1 conformation have been visualized by electron microscopy: The 433 
helical structure of the M1 layer in the virion is lost in acid-treated virions (Calder et 434 
al. 2010; Fontana et al. 2012). Before the loss of the M1 structure rearrangements in 435 
the M1 layer could be detected (Fontana and Steven 2013). It is currently unclear 436 
how the conformational change occurs but it was suggested that the linker region 437 
between the N- and C-terminal domain of M1 is important: In vitro the linker peptide 438 
changed its conformation upon pH drop but only in the presence of zinc ions, which 439 
have been detected in influenza virions  (Elster et al. 1994; Okada et al. 2003). Not 440 
much is known about the involvement of cellular factors in this process yet. Very 441 
recently, the E3 ubiquitin ligase Itch was reported to be required for efficient 442 
uncoating (Su et al. 2013). The authors could demonstrate that Itch gets 443 
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phosphorylated and recruited to endosomes upon IAV infection where it ubiquitinates 444 
M1 and thereby facilitates release of the vRNPs.  445 
Inhibitors of uncoating 446 
Amantadine is the best known example for an inhibitor of M2. Its antiviral activity was 447 
first described in 1964 (Davies et al. 1964). Later it was found that it targets the M2 448 
protein of influenza A virus and thereby exerts its antiviral function (Skehel et al. 449 
1978; Hay et al. 1985). Rimantadine is structurally similar and also blocks M2; 450 
together this drug class is called adamantanes. Unfortunately, resistance to the 451 
adamantanes can be achieved by just a single amino acid change in M2 and this has 452 
no or very little impact on viral fitness (Hay et al. 1986; Hayden et al. 1991; Sweet et 453 
al. 1991). Moreover, resistance to the adamantanes is widespread since the 454 
beginning of the 21st century  and therefore current guidelines do not recommend the 455 
use of adamantanes (Bright et al. 2005). A recent study reported on the development 456 
of novel M2 inhibitors that can block adamantane-sensitive as well as resistant 457 
strains (Wang et al. 2013). It is therefore conceivable that novel M2-inhibiting drugs 458 
might become available for clinical use in the future (table 2).  459 
 460 
NUCLEAR IMPORT OF VIRAL RNPs 461 
Import of vRNPs into the nucleus 462 
After completion of the uncoating process the RNPs are transported into the nucleus. 463 
Already early studies observed that NP accumulates in the nucleus while M1 464 
distributes between cytoplasm and nucleus (Martin and Helenius 1991). Given the 465 
size of the vRNPs it was hypothesized that an active, energy-dependent process 466 
would mediate their import. Of note, also RNPs microinjected into the cytoplasm of 467 
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cells were capable of entering the nucleus (Kemler et al. 1994). In 1995, O’Neill and 468 
co-workers demonstrated that the viral RNA was not able to enter the nucleus; 469 
addition of NP was required. Moreover, they could show that at 0°C NP docks to the 470 
nuclear envelope in the presence of karyopherins and is imported into the nucleus 471 
upon addition of the cellular import factors Ran and p10 proteins and a temperature 472 
shift to 20°C (O'Neill et al. 1995). This clearly showed that viral RNPs are imported 473 
via the cellular karyopherin import pathway. All protein components of the RNP, the 474 
three polymerase subunits and NP, possess nuclear localization signals (NLS). 475 
Nevertheless,  import of the RNP only depends on the NLS in NP (O'Neill et al. 1995; 476 
Cros and Palese 2003). First, an unconventional NLS in the N-terminus was 477 
described in NP (Wang et al. 1997). Later on, a second bi-partite NLS was identified 478 
between amino acids 198-216 (Weber et al. 1998) as well as a third one around 479 
amino acids 320-400 (Bullido et al. 2000). For import of the RNPs the unconventional 480 
NLS seems to be the most important one (Cros and Palese 2003). On the cellular 481 
side karyopherins alpha 1, alpha 3 and alpha 5 have been identified as the main 482 
importins for RNPs (table 1) (O'Neill et al. 1995; Wang et al. 1997; Melen et al. 2003). 483 
Also CSE1L, a cellular factor required for cycling of karyopherins between nucleus 484 
and cytoplasm, has been shown to be required for import of RNPs early in infection 485 
(Konig et al. 2010). Later in infection when the individual polymerase proteins get 486 
imported the NLS on the polymerase subunits become important and other 487 
karyopherins are involved. This topic is reviewed in (Hutchinson and Fodor 2012). 488 
Upon import into the nucleus the karyopherins bind to RanGTP, which results in 489 
release of cargo and this marks the end of the viral entry process.  490 
  491 
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OUTLOOK 492 
Entry of IAV into target cells is the very first step of the viral life cycle and as such is 493 
crucial for the establishment of infection. The receptor specificity of the virus’ HA 494 
determines tropism of the virus, thereby contributing to outcome of disease, and 495 
potentially virus spread between susceptible hosts. In recent years our understanding 496 
of the differential receptor specificity between avian and mammalian influenza 497 
viruses has greatly improved and exciting structural insights have been obtained. 498 
However, more work is still required to fully understand and predict receptor 499 
specificity of all HA subtypes. For entry into target cells the virus relies on and 500 
exploits existing cellular pathways of transporting cargo, thus the entry process is a 501 
complex interplay between virus and host cell. Advances in live cell microscopy are 502 
of great value in tracking virions during entry in real-time and in monitoring the 503 
interaction of the virus with cellular factors and compartments. Novel findings indicate 504 
that virus uptake and -trafficking may not be equal to that of other cargo transported 505 
into the cell. Instead, IAV specifically recruits factors facilitating entry and activates 506 
signaling molecules such as RTKs within minutes after infection. Future studies will 507 
shed light on how these host factors contribute to virus entry on a molecular level. 508 
The increasing insight into these processes can be exploited to develop means of 509 
inhibiting the virus early in infection. Novel treatment options may be specifically 510 
directed against IAV, or be of broad antiviral efficacy if targeting entry routes used by 511 
several viruses. In the near future, we may obtain a detailed insight into the cell 512 
biology of IAV entry and profit from newly developed antivirals targeting host factors 513 
rather than viral proteins, thereby minimizing the occurrence of resistance as 514 
observed with the M2 and NA inhibitors. 515 
 516 
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Figure legends 978 
Fig. 1: Schematic representation of the influenza A virus entry process. 979 
Fig. 2: Structure of hemagglutinin 980 
a) Structure of the hemagglutinin of influenza A virus A/SouthCarolina/1918 based on 981 
(Gamblin et al. 2004; PDB accession no. 1RUZ). The trimeric complex of HA is 982 
shown with one monomer highlighted in colour. HA1 is depicted in red, HA2 in blue 983 
and the receptor binding site in green. 984 
b) The pre- and post fusion conformations of HA are shown (Bullough et al. 1994; 985 
PDB accession no. 1HTM). For the post fusion conformation only the structure of the 986 
part represented in blue could be resolved. HA1 was not included in the structure and 987 
was modelled on according to (Palese and Shaw 2007). 988 
Fig. 3: Super resolution microscopy of influenza A virus in endosomes 989 
A549 lung epithelial cells were infected with influenza A virus (A/WSN/33, MOI of 25) 990 
for 30-180 minutes. Virus was added to the cells in an inital cold binding step to 991 
synchronize the infection process. Cells were fixed and stained for DAPI and NP (a), 992 
DAPI, NP and EEA1 (b1) or NP and EEA1 (b2-b4). Images were acquired by 993 
standard immunofluorescence microscopy (CLSM – confocal laser scanning 994 
microscopy, a, b1) or super resolution microscopy (STED – stimulated emission 995 
depletion, b2-b4). In b3-b4 rendered (IMARIS) images of viral particles within 996 
endosomes are shown. In b4 the transparency of the endosomal staining was 997 
increased to allow visibility of viral particles inside the respective endosome.   998 
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Table 1: Host factors involved in IAV entry 
host factor entry strep reference 
sialic acid attachment Palese and Shaw, 2007 
C-type lectins attachment reviewed by Londrigan et al., 2011 
annexin V attachment Huang et al., 1996 
6-sulfo sialyl Lewis X attachment Gambaryan et al., 2008 
dynamin internalization Roy et al., 2000(Roy et al. 2000) 
actin internalization 
Gottlieb et al., 1993(Gottlieb et al. 
1993) 
clathrin internalization Matlin et al., 1981 
epsin-1 internalization Chen et al., 2008 
EGFR internalization Eierhoff et al.., 2010 
c-Met kinase internalization Eierhoff et al., 2010 
PLC-γ1 internalization Zhu et al., 2013 
Rab 5 endosomal trafficking Sieczkarski et al., 2003 
Rab7 endosomal trafficking Sieczkarski et al., 2003 
PKC βII endosomal trafficking Sieczkarski et al., 2003 
cullin 3 endosomal trafficking Huotari et al., 2012 
HDAC8 endosomal trafficking Yamauchi et al., 2011 
vATPase endosomal acidification 
Guinea et al., 1995(Guinea and 
Carrasco 1995) 
CD81 fusion He et al., 2013 
ITCH uncoating Su et al., 2013 
karyopherin (α1; α3; α5) import Wang et al., 1997 
Ran import O’Neill et al., 1995 
p10 import O’Neill et al., 1995 
CSE1L import Konig et al., 2010 
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Table 2: Inhibitors of IAV entry 
 
inhibitor entry step potential as drug reference 
mAbs (HA-RBP) attachment yes reviewed by 
Clementi et al., 2012 
(Clementi et al. 
2012) 
SA mimics attachment yes reviewed by 
Vanderlinden et al.,  
2013 (Vanderlinden 
and Naesens 2013) 
SA binders attachment yes reviewed by 
Vanderlinden et al.,  
2013 
Sialidases 
e.g. DAS181 
attachment yes/phase II trial reviewed by Nicholls 
et al., 2013 
Dynasore internalization laboratory use De Vries et al., 2011 
EIPA internalization laboratory use De Vries et al., 2011 
Receptor tyrosine 
kinase inhibitors 
internalization  Eierhoff et al., 2010 
and De Vries et al., 
2012 
Lj001 internalization yes Wolf et al., 2010 
Bafilomycin A1 endosomal 
acidification 
laboratory use Guinea et al., 1995 
mAbs (HA stalk) fusion yes reviewed by Corti et 
al., 2013 (Corti and 
Lanzavecchia 2013) 
Small molecule 
inhibitors (HA 
stalk) 
fusion yes reviewed by 
Vanderlinden et al., 
2013 
Amantadine uncoating approved Davies et al., 1964 
Rimantadine uncoating approved Rabinovich et al., 
1969 (Rabinovich et 
al. 1969) 
benzyl-substituted 
amantadine 
derivatives 
uncoating yes Wang et al., 2013 
importazole import laboratory use Chou et al., 2013 
(Chou et al. 2013) 
 
 

Figure 2: Kinetics of IAV entry
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Figure 3: Super resolution microscopy of influenza A virus in endosomes
A) CLSM B) STED
early endosomes2 µm
C)STED rendered
Influenza A virus
0.5 µm
D)STED rendered
2 µm0 5 µm  .  
A549 lung epithelial cells were infected with influenza A virus (A/WSN/33, MOI of 25) for 60 minutes. Virus was added to the cells in an inital cold binding step to synchronize the
infection process. Cells were fixed and (A) standard immunofluorescence microscopy (CLSM – confocal laser scanning microscope) for DAPI, NP and EEA1 signal or (B‐D) super resolution
microscopy (STED – stimulated emission depletion) for NP and EEA1 was carried out. In C/D rendered (IMARIS) images of viral particles within endosomes are shown. In D the
transparency of the endosomal staining was increased to allow visibility of viral particles inside the respective endosome.
